Welcome to our dedicated page for Heartbeam SEC filings (Ticker: BEAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartBeam, Inc. filings document material events for a Nasdaq-listed medical technology issuer with common stock under BEAT and warrants under BEATW. Its 8-K disclosures cover underwriting agreements and common-stock offering terms, emerging growth company status, and FDA-related correspondence for its 12-Lead ECG Synthesis Software.
These records also identify capital-structure changes and formal event disclosures tied to commercialization and regulatory development of HeartBeam's 3D ECG technology.
HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.
According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.
Nelson Kenneth Warwick III reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. director Nelson Kenneth Warwick III reported a compensation grant of 17,241 restricted stock units (RSUs) of common stock. These RSUs were granted on February 9, 2026 at no cash cost and increase his direct holdings to 144,388 shares.
According to the grant terms, one half of the RSUs will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The award was issued under HeartBeam’s 2022 Equity Incentive Plan, highlighting routine equity-based director compensation rather than an open-market purchase.
HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.
According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.
HeartBeam, Inc. has amended its shelf registration to permit offers and sales of up to $100,000,000 of common stock, preferred stock, debt securities, warrants, rights and units from time to time. The prospectus notes $78,844,988 of securities previously registered remain unsold pursuant to Rule 415(a)(6).
Each offering will be described in a prospectus supplement setting forth amounts, prices, methods of sale and proceeds treatment. Shares outstanding were 41,087,871 common shares as of March 11, 2026, which the prospectus states as a company baseline figure.
HeartBeam, Inc. is a development-stage medical technology company focused on portable, cable‑free 12‑lead ECG systems for ambulatory cardiac monitoring. Its HeartBeam System, a credit card–sized 3D ECG device with cloud software and physician portal, received FDA clearance for arrhythmia assessment in December 2024 and for 12‑lead synthesis software in December 2025.
The company generated no revenue in 2025 and had 16 employees as of December 31, 2025, growing to 17 in early 2026 with the hire of a Chief Commercial Officer to lead commercialization. Management and the auditor highlight substantial doubt about HeartBeam’s ability to continue as a going concern, citing limited working capital and the need for additional financing, which may be dilutive.
HeartBeam plans a limited U.S. launch in early 2026 targeting concierge and preventive cardiology practices, while pursuing expanded indications such as heart attack detection, an extended‑wear 12‑lead patch, and AI‑based diagnostic algorithms. The company operates in a large, growing cardiac monitoring market and reports a broad patent portfolio, including 25 issued patents worldwide and multiple pending applications protecting its 3D ECG, patch, smartwatch and AI technologies.
HeartBeam, Inc. has filed a shelf registration statement on Form S-3 to offer and sell up to $100,000,000 of securities over time. The shelf covers common stock, preferred stock, debt securities, warrants, rights and units, to be issued in one or more future offerings.
HeartBeam is a medical technology company focused on ambulatory cardiac monitoring, using a proprietary 3D ECG platform that synthesizes a 12-lead ECG in a portable, credit card-sized device. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BEAT and BEATW, respectively. As of December 31, 2025, the company had 40,117,404 shares of common stock outstanding and 3,162,500 exchange-listed warrants with a $6 exercise price.
HeartBeam, Inc. reported that on November 20, 2025 it received a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration regarding its 510(k) application for its 12-Lead Electrocardiogram (ECG) Synthesis Software. An NSE letter means the FDA did not find the device substantially equivalent to a predicate device under this submission. The company stated that it stands behind its clinical data and plans to work with the FDA to reach a resolution. HeartBeam also noted it is evaluating the launch of its novel 3D ECG system, which previously received FDA 510(k) clearance in December 2024.
HeartBeam, Inc. reported third‑quarter results showing a net loss of $5.3 million and reiterated substantial doubt about its ability to continue as a going concern based on current cash resources. Cash and cash equivalents were $1.856 million, with cash used in operations of $11.1 million for the first nine months.
Operating expenses were $5.29 million in the quarter, as R&D rose while G&A declined. Year‑to‑date, the company raised $10.25 million net in a February public offering and $0.49 million via its ATM program. The ATM capacity remaining was approximately $15.5 million, potentially subject to baby shelf limitations.
HeartBeam received FDA clearance in December 2024 for its initial ambulatory ECG system and filed a 510(k) in January 2025 for its 12‑lead synthesis software. It launched an early access program for user feedback and highlighted AI study data supporting arrhythmia classification. Common shares outstanding were 34,340,727 as of September 30, 2025; shares outstanding were 34,443,563 as of November 11, 2025.
HeartBeam, Inc. (BEAT) CFO Tim Cruickshank reported a Form 4 showing a sale of 17,647 shares of Common Stock and a grant of 23,333 Restricted Stock Units (RSUs) on 09/30/2025. The RSUs were issued under the company’s 2022 Equity Incentive Plan and vest in two equal tranches: one half on the three‑month anniversary of the vesting commencement date (July 1, 2025 start) and the remainder on the six‑month anniversary. The filing notes RSUs do not expire and are either vested or canceled. The report was signed by the reporting person on 10/03/2025.